Literature DB >> 1323695

A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

B Wagner1, B Kropff, H Kalbacher, W Britt, V A Sundqvist, L Ostberg, M Mach.   

Abstract

Antigenic domain 1 (AD-1) on glycoprotein gp58 of human cytomegalovirus was characterized in detail, using mouse and human monoclonal antibodies as well as human convalescent sera. Series of procaryotically expressed fusion proteins and synthetic peptides of various lengths were used as sources of antigen. Binding of antibodies was found to depend on a continuous sequence of more than 70 amino acids between residues 552 and 635 of gp58. The fine specificities for sequences involved in antibody binding were (i) amino acids 557 to 635 for neutralizing as well as nonneutralizing mouse monoclonal antibodies, (ii) amino acids 552 to 630 for a neutralizing human monoclonal antibody, and (iii) amino acids 557 to 630 for antibodies present in human sera. Experiments involving fragments of AD-1, presented either as procaryotically expressed fusion protein or as synthetic peptides, indicated that the intact structure was required for recognition of AD-1 by antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323695      PMCID: PMC289083     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  pSEM vectors: high level expression of antigenic determinants and protein domains.

Authors:  S Knapp; M Bröker; E Amann
Journal:  Biotechniques       Date:  1990-03       Impact factor: 1.993

2.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

3.  Cleavage and purification of prokaryotically expressed HIV gag and env fusion proteins for detection of HIV antibodies in the ELISA.

Authors:  S Ellinger; M Mach; K Korn; G Jahn
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

Review 4.  Vaccines for the prevention of human cytomegalovirus infection.

Authors:  S A Plotkin; S E Starr; H M Friedman; E Gonczol; K Brayman
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

Review 5.  Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.

Authors:  M S Chee; A T Bankier; S Beck; R Bohni; C M Brown; R Cerny; T Horsnell; C A Hutchison; T Kouzarides; J A Martignetti
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

6.  Biochemical and immunological analysis of discontinuous epitopes in the family of human cytomegalovirus glycoprotein complexes designated gC-I.

Authors:  B Kari; R Gehrz
Journal:  J Gen Virol       Date:  1991-08       Impact factor: 3.891

7.  Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp58) in clinical isolates of human cytomegalovirus.

Authors:  J Darlington; M Super; K Patel; J E Grundy; P D Griffiths; V C Emery
Journal:  J Gen Virol       Date:  1991-08       Impact factor: 3.891

8.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope.

Authors:  H Meyer; Y Masuho; M Mach
Journal:  J Gen Virol       Date:  1990-10       Impact factor: 3.891

10.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

View more
  22 in total

1.  Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Authors:  Elizabeth A Reap; Sergey A Dryga; John Morris; Bryan Rivers; Pamela K Norberg; Robert A Olmsted; Jeffrey D Chulay
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

2.  Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Authors:  Elizabeth A Reap; John Morris; Sergey A Dryga; Maureen Maughan; Todd Talarico; Robert E Esch; Sarah Negri; Bruce Burnett; Andrew Graham; Robert A Olmsted; Jeffrey D Chulay
Journal:  Vaccine       Date:  2007-08-30       Impact factor: 3.641

3.  Anti-idiotypic mimicry of a neutralizing epitope on the glycoprotein B complex of human cytomegalovirus.

Authors:  E S Tackaberry; J Hamel; Y Larose; B R Brodeur
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

4.  Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.

Authors:  Nina Reuter; Barbara Kropff; Julia Karin Schneiderbanger; Mira Alt; Adalbert Krawczyk; Christian Sinzger; Thomas H Winkler; William J Britt; Michael Mach; Marco Thomas
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

5.  Disulfide bonds of herpes simplex virus type 2 glycoprotein gB.

Authors:  N Norais; D Tang; S Kaur; S H Chamberlain; F R Masiarz; R L Burke; F Marcus
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.

Authors:  William J Britt; Michael A Jarvis; Derek D Drummond; Michael Mach
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus.

Authors:  Nadja Spindler; Pia Rücker; Sonja Pötzsch; Uschi Diestel; Heinrich Sticht; Luis Martin-Parras; Thomas H Winkler; Michael Mach
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

8.  Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent.

Authors:  M A Jarvis; C E Wang; H L Meyers; P P Smith; C L Corless; G J Henderson; J Vieira; W J Britt; J A Nelson
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 9.  Investigation of CMV disease in immunocompromised patients.

Authors:  V C Emery
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

10.  Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.

Authors:  K D Greis; W Gibson; G W Hart
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.